Share this article on:

Donor Human Milk for Preterm Infants: Current Evidence and Research Directions

Arslanoglu, Sertac*,†; Corpeleijn, Willemijn; Moro, Guido*; Braegger, Christian§; Campoy, Cristina||; Colomb, Virginie; Decsi, Tamas#; Domellöf, Magnus**; Fewtrell, Mary††; Hojsak, Iva‡‡; Mihatsch, Walter§§; Mølgaard, Christian||||; Shamir, Raanan¶¶; Turck, Dominique##; van Goudoever, JohannesESPGHAN Committee on Nutrition

Journal of Pediatric Gastroenterology and Nutrition: October 2013 - Volume 57 - Issue 4 - p 535–542
doi: 10.1097/MPG.0b013e3182a3af0a
Society Commentary

ABSTRACT The Committee on Nutrition of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition aims to document the existing evidence of the benefits and common concerns deriving from the use of donor human milk (DHM) in preterm infants. The comment also outlines gaps in knowledge and gives recommendations for practice and suggestions for future research directions. Protection against necrotizing enterocolitis is the major clinical benefit deriving from the use of DHM when compared with formula. Limited data also suggest unfortified DHM to be associated with improved feeding tolerance and with reduced cardiovascular risk factors during adolescence. Presence of a human milk bank (HMB) does not decrease breast-feeding rates at discharge, but decreases the use of formula during the first weeks of life. This commentary emphasizes that fresh own mother's milk (OMM) is the first choice in preterm infant feeding and strong efforts should be made to promote lactation. When OMM is not available, DHM is the recommended alternative. When neither OMM nor DHM is available, preterm formula should be used. DHM should be provided from an established HMB, which follows specific safety guidelines. Storage and processing of human milk reduces some biological components, which may diminish its health benefits. From a nutritional point of view, DHM, like HM, does not meet the requirements of preterm infants, necessitating a specific fortification regimen to optimize growth. Future research should focus on the improvement of milk processing in HMB, particularly of heat treatment; on the optimization of HM fortification; and on further evaluation of the potential clinical benefits of processed and fortified DHM.

*Italian Association of Human Milk Banks, Milan, Italy

Division of Neonatology, İzmir Dr Behçet Uz Children's Hospital, İzmir, Turkey

Paediatrics, VU University Medical Center, Amsterdam, the Netherlands, and Paediatrics, Emma Children's Hospital-AMC, Amsterdam, The Netherlands

§University Children's Hospital, Zurich, Switzerland

||Department of Paediatrics, University of Granada, Granada, Spain

Hospital Necker Paris, Paris, France

#Department of Paediatrics, University of Pecs, Pecs, Hungary

**Department of Clinical Sciences, Paediatrics, Umeå University, Umeå, Sweden

††MRC Childhood Nutrition Research Centre, UCL Institute of Child Health, London, UK

‡‡Referral Center for Pediatric Gastroenterology and Nutrition, Children's Hospital Zagreb, Zagreb, Croatia

§§Department of Paediatrics, Harlaching, Munich Municipal Hospitals, Munich, Germany

||||Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Denmark

¶¶Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

##Jeanne de Flandre Children's Hospital, Lille University Faculty of Medicine, Lille, France.

Address correspondence and reprint requests to Sertac Arslanoglu, MD, Associate Professor of Neonatology, Division of Neonatology, İzmir Dr. Behçet Uz Children's Hospital, İzmir 35210, Turkey (e-mail:

Received 11 June, 2013

Accepted 11 June, 2013

Drs Arslanoglu, Corpeleijn, and Moro are the guests; Dr Mihatsch is a Committee secretary; and Dr Goudoever is a Committee chairman.

The authors report no conflicts of interest.

© 2013 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology,